Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + docetaxel versus placebo + docetaxel in metastatic castration-resistant prostate cancer
2023-504996-26-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Capivasertib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
capivasertibdocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-504996-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504996-26-00.